RecruitingNot Applicable

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

United States1,000 participantsStarted 2010-04

Plain-language summary

This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male and female recipients of all races, ≥18 years of age.
✓. Patients undergoing primary or subsequent living or deceased donor liver transplantation.
✓. Subject and/or guardian must be able to provide informed consent.
✓. Subject and/or guardian must be able to comply with the study protocol.

What they're measuring

Proteogenomic Biomarkers for CKD, AR and HCV

Timeframe: At time of liver biopsy

Trial details

NCT IDNCT01644903

SponsorNorthwestern University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-12

Contact for this trial

Misael Villegas, BA

misael.villegas@northwestern.edu

View on ClinicalTrials.gov More Liver Transplant trials